MammaPrint and BluePrint identify critical aspects of tumor biology in African-Americ
 

Agendia, Inc., a world leader in precision oncology, today announced the presentation of study results for BluePrint and MammaPrint use in identifying African-American women with hormone receptor positive tumors that have different genomic subtypes and risk than Caucasian women.

More...